A groundbreaking study presented at the American College of Cardiology's Annual Scientific Session reveals that diabetic patients without known heart disease can significantly reduce their risk of a first heart attack or stroke by aggressively lowering their cholesterol levels early, before atherosclerosis develops. The findings challenge the traditional approach of waiting until someone has already suffered a cardiac event to prescribe intensive cholesterol-lowering therapy.

What Did the Study Actually Show?

Researchers analyzed data from over 3,600 participants with diabetes who had no known significant buildup of plaque in their heart's arteries, a condition called atherosclerosis. These patients received either evolocumab, a cholesterol-lowering medication, or a placebo, and were followed for a median of 4.8 years . The results were striking: patients taking evolocumab experienced a 31% reduction in major adverse cardiac events, which include heart attack, stroke, and death from heart disease. This benefit appeared within the first year and actually grew stronger over time, reaching approximately 40% risk reduction after the first year .

Among the subset of patients whose cholesterol levels were monitored throughout the study, those receiving evolocumab saw their LDL cholesterol (the "bad" cholesterol that contributes to plaque buildup) drop dramatically. Their levels fell to a median of 52 mg/dL at 48 weeks and 44 mg/dL at 96 weeks, compared to 111 mg/dL and 105 mg/dL in the placebo group . Additionally, patients on evolocumab were 32% less likely to die from cardiovascular causes and 24% less likely to die from any cause during the study period .

How Does Evolocumab Work to Protect the Heart?

Evolocumab is an injectable monoclonal antibody that works by blocking a protein called PCSK9. This blockade increases the number of LDL receptors in the liver, allowing the organ to remove more LDL cholesterol from the bloodstream. By substantially reducing LDL cholesterol levels, a major contributor to plaque buildup in arteries, evolocumab helps slow the progression of atherosclerosis and prevents serious cardiac events .

The VESALIUS-CV trial, from which this analysis was drawn, enrolled 12,257 patients with an LDL cholesterol level of 90 mg/dL or higher who had either known atherosclerosis or diabetes and had not previously suffered a heart attack or stroke. This was the first major trial to assess evolocumab's use in primary prevention, meaning in patients who had not yet experienced a major cardiac event .

Why This Changes How Doctors Should Treat Diabetes and Heart Risk

The implications of this research are significant. Traditionally, PCSK9 inhibitors like evolocumab have been reserved for patients who have already suffered a heart attack or stroke. However, this study demonstrates clear benefits in a much broader population: diabetic patients without known atherosclerosis who are at high risk but have not yet experienced a cardiac event.

"I think this study changes the paradigm. In current practice, PCSK9 inhibitors are largely reserved for patients who have had a prior heart attack or stroke, but here we see a benefit of using evolocumab not only to treat patients without a history of heart attack or stroke, but without known significant atherosclerosis. It's a message to physicians and patients that we don't have to wait until someone has atherosclerosis to treat them intensively. We can and should be much more proactive," said Nicholas Marston, MD, MPH, cardiologist and assistant professor of medicine at Brigham and Women's Hospital and Harvard Medical School in Boston and the study's lead author.

Nicholas Marston, MD, MPH, Assistant Professor of Medicine at Brigham and Women's Hospital and Harvard Medical School

Marston further noted that the field has been moving toward lower LDL cholesterol goals over the decades, and the benefits have continued to accumulate. "Over the decades, we've moved to lower and lower LDL-C goals, and we've continued to see benefit. Now, we're in this process of moving earlier and earlier in the disease course, and so far, we're continuing to see benefit from that approach," he explained .

Steps to Take If You Have Diabetes and High Cholesterol Risk

• Get Your Cholesterol Checked: If you have diabetes, ensure your LDL cholesterol levels are measured regularly. The study focused on patients with LDL cholesterol of 90 mg/dL or higher, which is considered elevated for someone with diabetes.
• Talk to Your Doctor About Intensive Treatment: Based on these findings, discuss with your primary care provider whether you might benefit from more aggressive cholesterol-lowering therapy, even if you haven't had a heart attack or stroke.
• Consider Statin Therapy First: The study noted that 87% of participants were already taking a statin, which is typically the first-line treatment for high cholesterol. Make sure you're on an optimally tolerated dose before considering additional medications.
• Ask About PCSK9 Inhibitors: If you have diabetes and high cardiovascular risk, ask your doctor whether a PCSK9 inhibitor like evolocumab might be appropriate for you, particularly if statins alone aren't achieving your target cholesterol levels.

The study's findings align with updated guidelines. The American College of Cardiology and American Heart Association released new dyslipidemia management guidelines earlier this month that recommend lower LDL cholesterol levels earlier in life . These guidelines bring back specific LDL cholesterol and non-HDL cholesterol treatment targets to guide therapy decisions.

What Are the Limitations of This Research?

While the findings are compelling, researchers acknowledged some limitations. The study population was primarily older adults with a median age of 65 years, and 93% were White, which means the results may not apply equally to younger patients or those from other racial and ethnic backgrounds . Additionally, coronary imaging was not required for study enrollment, so it's possible some participants had undiagnosed atherosclerotic heart disease. However, this reflects real-world clinical practice, where routine coronary imaging is not recommended for all patients .

Researchers noted that additional studies could clarify whether evolocumab provides similar benefits for younger patients or those with other cardiovascular risk factors beyond diabetes .

The bottom line: if you have diabetes, your cholesterol management deserves serious attention, even if you haven't experienced a heart attack or stroke. This research suggests that treating cholesterol aggressively and early, before atherosclerosis develops, could prevent a significant portion of heart disease in the diabetic population. Talk to your doctor about whether you're on the right cholesterol-lowering therapy for your individual risk profile.